Anticancer Therapies – Products

Personalis has announced a collaboration with UC San Francisco that will deploy a personalized liquid biopsy-based research use only assay for a study of patients with colorectal cancer.

Actym Therapeutics has announced that an abstract highlighting detailed preclinical data of its lead candidate, ACTM-838, was accepted for presentation at the Society for Immunotherapy of Cancer 37th Annual Meeting.

OncoHost has developed a novel predictive model for clinical benefit of immune checkpoint inhibitor in non-small cell lung cancer patients.

The MACSima™ Imaging Platform opens the next level of context in spatial biology, allowing fully automated imaging of 100s of protein markers on a single tissue sample. It includes a broad portfolio of pre-validated antibodies and an easy-to-use software generating ready-to-publish images and charts.

Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary and promising approach for cancer treatment. However, its potential is limited by technical challenges and safety risks associated with viral transduction–based CAR T-cell generation workflows.

PerkinElmer, Inc. has launched the Cellaca® PLX Image Cytometry System, a first-of-its-kind benchtop platform that enables researchers to assess multiple critical quality attributes of cell samples in a single automated workflow, including cell identity, quality and quantity.

Multisite study will test sonodynamic therapy in pediatric patients with diffuse intrinsic pontine glioma (DIPG).

It has proven difficult to accurately identify the biological targets of cancer, which are necessary for the development of successful therapeutics including novel immunotherapies, such as those based on chimeric antigen receptor (CAR) T cells.

CapnoPharm is proud to announce its selection as a finalist of the prestigious Reuters Pharma Europe Award 2022 for its Cancer drug delivery innovation - Capnodrug® - in the Health Entrepreneur Award category.

Avacta Group plc announces that the US Food and Drug Administration has granted Orphan Drug Designation to the company’s lead pre|CISION drug candidate, AVA6000, for treatment of soft tissue sarcoma.